Citations (24)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (8)
Matteo Megna, Luca Potestio, Gabriella Fabbrocini & Angelo Ruggiero. (2022) Long-Term Efficacy and Safety of Guselkumab for Moderate to Severe Psoriasis: A 3-Year Real-Life Retrospective Study. Psoriasis: Targets and Therapy 12, pages 205-212.
Read now
Read now
Angelo Ruggiero, Luca Potestio, Elisa Camela, Gabriella Fabbrocini & Matteo Megna. (2022) Bimekizumab for the Treatment of Psoriasis: A Review of the Current Knowledge. Psoriasis: Targets and Therapy 12, pages 127-137.
Read now
Read now
Angelo Ruggiero, Fabrizio Martora, Gabriella Fabbrocini, Alessia Villani, Claudio Marasca, Matteo Megna, Luigi Fornaro, Rosita Comune & Luca Potestio. (2022) The Role of Teledermatology During the COVID-19 Pandemic: A Narrative Review. Clinical, Cosmetic and Investigational Dermatology 15, pages 2785-2793.
Read now
Read now
Angelo Ruggiero, Vincenzo Picone, Fabrizio Martora, Gabriella Fabbrocini & Matteo Megna. (2022) Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence. Clinical, Cosmetic and Investigational Dermatology 15, pages 1649-1658.
Read now
Read now
Cataldo Patruno, Luca Potestio, Massimiliano Scalvenzi, Teresa Battista, Flavia Raia, Vincenzo Picone, Gabriella Fabbrocini & Maddalena Napolitano. (2022) Dupilumab for the treatment of adult atopic dermatitis in special populations. Journal of Dermatological Treatment 33:7, pages 3028-3033.
Read now
Read now
Maddalena Napolitano, Luca Potestio, Francesca Di Vico, Gabriella Fabbrocini & Cataldo Patruno. (2022) Letter to the editor submitted in response to ‘Incidence and prognosis of COVID-19 in patients with atopic diseases on dupilumab: a multicentre retrospective cohort study’. Journal of Dermatological Treatment 33:7, pages 3066-3067.
Read now
Read now
Martina Kojanova, Milena Tanczosova, Daniela Strosova, Petra Cetkovska, Jorga Fialova, Tomas Dolezal, Alena Machovcova & Spyridon Gkalpakiotis. (2022) Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry. Journal of Dermatological Treatment 33:5, pages 2578-2586.
Read now
Read now
Justyna Ceryn, Michał Niedźwiedź, Małgorzata Skibińska, Magdalena Ciążyńska, Aleksandra Lesiak & Joanna Narbutt. (2021) COVID-19 in Patients with Atopic Dermatitis Treated with Dupilumab: Three Cases and a Literature Review. Clinical, Cosmetic and Investigational Dermatology 14, pages 1131-1138.
Read now
Read now
Articles from other publishers (16)
Colver Ken Howe Ne, Noor Hidayatul Aini Suaini, Win Thu Aung, Kevin Gheng Seong Ong, Miny Samuel & Elizabeth Huiwen Tham. (2024) Impact of COVID-19 pandemic on adults and children with atopic dermatitis and food allergy: Systematic review. Journal of Allergy and Clinical Immunology: Global 3:1, pages 100181.
Crossref
Crossref
Christina E. Zielinski. (2023) T helper cell subsets: diversification of the field. European Journal of Immunology.
Crossref
Crossref
Angelo Ruggiero, Alessia Villani, Gabriella Fabbrocini & Fabrizio Martora. (2022) Reply to: “Usage and perceptions of teledermatology in 2021: a survey of dermatologists” by Ahmad et al.. International Journal of Dermatology 62:2.
Crossref
Crossref
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini & Sonia Sofia Ocampo-Garza. (2023) Anti-IL23 biologic therapies in the treatment of psoriasis: real-world experience versus clinical trials data. Immunologic Research.
Crossref
Crossref
Valencia Long, Ellie Ci-En Choi, Zhaojin Chen, Moonyza Akmal Ahmad Kamil, Murlidhar Rajagopalan, Erin McMeniman & Nisha Suyien Chandran. (2022) Dermatologists’ Perceptions of The Use of Teledermatology in Managing Hidradenitis Suppurativa (Preprint). JMIR Dermatology.
Crossref
Crossref
Angelo Ruggiero, Matteo Megna, Gabriella Fabbrocini & Fabrizio Martora. (2022) Video and telephone teledermatology consultations during COVID-19 in comparison: patient satisfaction, doubts and concerns. Clinical and Experimental Dermatology 47:10, pages 1863-1864.
Crossref
Crossref
Matteo Megna, Luca Potestio, Elisa Camela, Gabriella Fabbrocini & Angelo Ruggiero. (2022) Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: Results from an Italian single‐center retrospective study in a real‐life setting. Dermatologic Therapy 35:9.
Crossref
Crossref
Fabrizio Martora, Vincenzo Picone, Teresa Battista, Gabriella Fabbrocini & Claudio Marasca. (2022)
Reply to “the significance of investigating clinical, histopathologic and virological features in pityriasis rosea and pityriasis rosea‐like eruptions following
COVID
‐19 vaccinations” by Ciccarese G. et al.
. Dermatologic Therapy 35:8.
Crossref
Crossref
Amr Ehab El‐Qushayri, Mariam Abdelmageed Mahmoud, Samar Salman, Sameh Sarsik & Beatrice Nardone. (2022) Dupilumab therapy in atopic dermatitis is safe during COVID‐19 infection era: A systematic review and meta‐analysis of 1611 patients. Dermatologic Therapy 35:6.
Crossref
Crossref
Hamida Hammad, Nincy Debeuf, Helena Aegerter, Andrew S. Brown & Bart N. Lambrecht. (2022) Emerging Paradigms in Type 2 Immunity. Annual Review of Immunology 40:1, pages 443-467.
Crossref
Crossref
Claudio Marasca, Maria Carmela Annunziata, Elisa Camela, Adriana Di Guida, Luigi Fornaro, Matteo Megna, Maddalena Napolitano, Cataldo Patruno, Luca Potestio & Gabriella Fabbrocini. (2022) Teledermatology and Inflammatory Skin Conditions during COVID-19 Era: New Perspectives and Applications. Journal of Clinical Medicine 11:6, pages 1511.
Crossref
Crossref
Khalaf Kridin, Yochai Schonmann, Arie Solomon, Erez Onn, Dana Tzur Bitan, Orly Weinstein & Arnon D. Cohen. (2021) Risk of COVID-19 and its complications in patients with atopic dermatitis undergoing dupilumab treatment—a population-based cohort study. Immunologic Research 70:1, pages 106-113.
Crossref
Crossref
Benjamin Ungar, Jacob W. Glickman, Alexandra K. Golant, Celina Dubin, Olga Marushchak, Alyssa Gontzes, Daniela Mikhaylov, Giselle K. Singer, Danielle Baum, Nancy Wei, Antonio Sanin, Diana Gruenstein, Mark G. Lebwohl, Ana B. Pavel & Emma Guttman-Yassky. (2022) COVID-19 Symptoms Are Attenuated in Moderate-to-Severe Atopic Dermatitis Patients Treated with Dupilumab. The Journal of Allergy and Clinical Immunology: In Practice 10:1, pages 134-142.
Crossref
Crossref
Teresa Grieco, Camilla Chello, Alvise Sernicola, Rovena Muharremi, Simone Michelini, Giovanni Paolino, Giorgia Carnicelli & Paolo Daniele Pigatto. (2021) Impact of COVID-19 on patients with atopic dermatitis. Clinics in Dermatology 39:6, pages 1083-1087.
Crossref
Crossref
Monica Fung, Iris Otani, Michele Pham & Jennifer Babik. (2021) Zoonotic coronavirus epidemics. Annals of Allergy, Asthma & Immunology 126:4, pages 321-337.
Crossref
Crossref
Maria Fernanda Ordóñez‐Rubiano, Isabela Campo & Mirian Casas. (2020)
Dupilumab in atopic dermatitis, a protocol for
SARS‐COV‐
2‐infected patients
. Dermatologic Therapy 33:6.
Crossref
Crossref